US and EU Secure Vaccine Production on Home Soil

Jan Malek, Melissa Newham, Jo Seldeslachts and Marcel Wieting

No 6, DIW focus from DIW Berlin, German Institute for Economic Research

Abstract: The deployment of a safe and effective vaccine for Covid-19 will be central to lifting containment measures. In a bid to speed up vaccine deployment, governments are entering into ‘Advance Purchase Agreements’ (APAs) with vaccine companies to secure access to vaccine doses. We document and compare the vaccine procurement strategies of the US and the EU. Most notably, we find that both the US and the EU only secure vaccine doses from developers whose (contracted) production facilities are based in US or EU territory, respectively. Securing vaccine production on home soil is crucial in a crisis because of the ability of governments to implement export restrictions; vaccines produced in a different jurisdiction may be blocked from exiting the region. Thus, only governments who can secure local production will be able to provide a vaccine quickly.

Pages: 8 p.
Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.diw.de/documents/publikationen/73/diw_01.c.798805.de/diw_focus_6.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:diw:diwfoc:6en

Access Statistics for this paper

More papers in DIW focus from DIW Berlin, German Institute for Economic Research Contact information at EDIRC.
Bibliographic data for series maintained by Bibliothek ().